FDA To Weigh Public Input On Biosimilars Program
The U.S. Food and Drug Administration said Monday it would hold a public hearing to seek stakeholder input on the agency's proposed user fee program for biosimilar biological products, a move...To view the full article, register now.
Already a subscriber? Click here to view full article